Gastric Cancer – Enhertu in HER2-Positive patients


Enhertu is a conjugate of an antibody which is anti-HER2 and chemo drug. Enhertu may have efficacy in patients with HER2-positive advanced gastric cancer.

In a phase II trial, Enhertu was evaluated as compared with chemotherapy in patients with HER2-positive advanced gastric cancer.

All patients who participated in the trial had progressed while they were receiving at least two previous therapies, including Herceptin.

Patients were randomly to receive Enhertu or physician’s choice of chemotherapy.


  • Of 187 treated patients, 125 received Enhertu and 62 received chemotherapy.
  • Among 51% of the patients in the Enhertu group had their cancer stopped from growing or shrunk as compared with 14% of those in the physician’s choice group.
  • Median survival with Enhertu was 12.5 months as compared with chemotherapy which was 8.4 months

Side Effects

The most common severe side effects were a decreased neutrophil count, anemia and decreased white-cell count.

A total of 12 patients had Enhertu-related Interstitial Lung Disease (ILD) or Pneumonitis.

One drug-related death (due to Pneumonia) was noted in the Enhertu groupץ

No drug-related deaths occurred in the physician’s choice group.


  • Therapy with Enhertu led to significant improvements in response and survival as compared with standard therapies, among patients with HER2-positive gastric cancer.
  • Myelosuppression and ILD were the notable side effects.

The best treatment for a cancer patient is to get the most advanced cancer drugs in advanced stages of development. There, the hope and the chance to extend life go far beyond the standard protocols.

Contact us to find out what is the best treatment for YOU


Because we, do not give up on life!

Contact us 24/7 –

Call center +44.2082.426.039

For further reading>>

About Gastric cancer

Gastric cancer, also called “Stomach cancer”, starts when some of the cells constituting the inner part of the stomach start growing and proliferating without control. This abnormal growth creates a tumor that is cancerous. Usually gastric cancer grows slowly, along a course of many years.

Cause of Gastric Cancer

At the present it is still unknown why some people contract the disease, while others don’t. However, it is known that bacteria, named “H. pylori” may increase the chance of contracting stomach cancer, as well as a stomach inflammation known as “Gastritis”, long term anemia known as “Pernicious anemia” and the formation of polyps in the stomach.


  • Indigestion
  • Feeling swollen after eating
  • Heartburn
  • Mild nausea
  • Loss of appetite

Gastric Cancer Treatment Objectives

The main objective of treatment is to slow down and control the disease’s progress and help reduce symptoms. For metastatic melanoma stage 4 the primary objective is to prolong life and improve patient’s quality of life.

The treatment will be determined according to a number of factors, including tumor size, location and stage of the disease, whether it is a recurrent disease or not and the general status of the patient.

In metastatic stage 4 disease, the primary objective of the treatment is to slow down and control disease progression and help reduce symptoms as well prolong life and improve patient’s quality of life.

Learn more about Gastric cancer>>

Gastric Cancer - Enhertu in HER2-Positive patients
Gastric Cancer – Enhertu in HER2-Positive patients

To check if our service suits your case
We need to talk

Improve therapeutic outcomes, prolong life and quality of life, is our main business.
We support access to and expand cancer treatments beyond the standard of care, with the most advanced and innovative treatment options in the world, personally matching the individual cancer patient’s medical condition and with the support of top tier oncologists.

Article categories

קטגוריות המאמרים

Popular topics